Evidence map›Paper›PMID 33706870›Full record

Trial reportJournal of the American College of Cardiology2021

Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension.

Nayyra Fatani, Dave L Dixon, Benjamin W Van Tassell, John Fanikos, Leo F Buckley

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American College of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 3 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 3 syntheses or guidelines pooled it, 149 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Time in target range of systolic blood pressure and eGFR slope in patients with type 2 diabetes.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022
    Trial
  15. Trial
  16. Observational
  17. Observational
  18. Asian expert consensus on high-quality hypertension management.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nayyra FataniDepartment of Clinical Pharmacy, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmacy Practice, MCPHS University, Boston, Massachusetts, USA; Department of Pharmacy Services, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Dave L DixonDepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, Virginia, USA.
Benjamin W Van TassellDepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, Virginia, USA.
John FanikosDepartment of Pharmacy Services, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Leo F BuckleyDepartment of Pharmacy Services, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: LFBuckley@bwh.harvard.edu.
Virginia Commonwealth University · USBrigham and Women's Hospital · US

Funding

Inflammasome Activity as a Potential Contributor to Uremic CardiomyopathyK23HL150311 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BUCKLEY, LEO FRANCIS · 2020 to 2024
$1.1M
NHLBI NIH HHS K23 HL150311
6 · The paper itself

Abstract

backgroundStandard blood pressure control metrics may not account for fluctuations in blood pressure over time.

objectivesThis study sought to estimate the independent association between time in systolic blood pressure target range and major adverse cardiovascular events among adults with hypertension.

methodsThis study was a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a randomized clinical trial that compared intensive (<120 mm Hg) and standard (<140 mm Hg) systolic blood pressure treatment interventions in adults with hypertension and high cardiovascular risk. Target range was defined as 110 to 130 mm Hg and 120 to 140 mm Hg for the intensive and standard arms, respectively. Time in target range was estimated over the first 3 months of follow-up using linear interpolation. The association between time in target range with major adverse cardiovascular events was estimated using adjusted Cox proportional hazards regression models.

resultsParticipants with greater time in target range were younger, had lower 10-year cardiovascular risk and lower baseline systolic blood pressure, and were more likely women and statin users. Each 1-SD increase in time in target range was significantly associated with a decreased risk of first major adverse cardiovascular event in fully adjusted models. Time in target range remained significantly associated with major adverse cardiovascular events despite adjustment for mean systolic blood pressure or systolic blood pressure variability. Among participants with mean systolic blood pressure at or below target, time in target range remained associated with major adverse cardiovascular events.

conclusionsTime in systolic blood pressure target range independently predicts major adverse cardiovascular event risk.

Indexed as

AgedAntihypertensive AgentsBlood PressureFemaleHumansHypertensionMaleMiddle AgedRetrospective StudiesAntihypertensive Agentshypertensionquality of caretime in target range

Identifiers

PMID33706870
PMCPMC7959178
OpenAlexW3135026334

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.